课题基金 / 基金详情

SCOR: Pathobiology of Fibrotic Lung Disease

SCOR: Pathobiology of Fibrotic Lung Disease
SCOR:纤维化肺病的病理学
批准号:
6912712
负责人:
ROBERT James MASON
金额:
$188.58万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-09-05 至 2007-01-31

项目摘要

项目成果

ROBERT James MASON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
(Applicant's Abstract) The overall purpose of this SCOR proposal is to investigate the role of the myofibroblast in idiopathic pulmonary fibrosis (IPF). We are particularly interested in defining the source and regulation of TGF-beta production, especially the contribution of the ingestion of apoptotic cells and cell debris, the relationship of paracrine factors and mechanical factors on myofibroblast gene regulation, the role of survival factors for myofibroblasts such as IGF- I and myofibroblast apoptosis, interactions of myofibroblasts with alveolar epithelial cells, and finally regulation by interferon gamma (INF). In the clinical portion of this SCOR proposal, Dr. Schwarz will evaluate INF in the treatment of idiopathic pulmonary fibrosis. A major aspect of this proposal will be to use DNA microarrays to define gene expression of specific cell types as well as alterations in fibrotic lung and microdissected fibroblastic foci in IPF and Masson bodies in BOOP. In project 1, Dr. Henson will study the regulation of TGF-beta production by the ingestion of apoptotic cells. This is a new biologic process for the production of TGF-beta. In project 2, Dr. Worthen will study the regulation of the myofibroblast phenotype especially the interaction between paracrine factors such as TGF-beta and mechanical stress. In project 3, Dr. Riches will determine the role of IGF-1 as a survival factor which prevents the apoptosis of myofibroblasts. In project 4, Dr. Mason will study the interactions between myofibroblasts and alveolar type II cells. A significant portion of this project is to define the interactions between KGF, TGF-beta, and INF on the alveolar epithelium. In project 5, Dr. Schwarz will determine the clinical efficacy of INF as therapy for idiopathic pulmonary fibrosis, myofibroblast proliferation and apoptosis in IPF, and gene expression in fibroblastic foci in IPF and Masson bodies of BOOP.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Air/liquid interface cultures for alveolar type II cell differentiation
  • 批准号:
    8191639
  • 项目类别:
  • 资助金额:
    $23.78万
  • 财政年份:
    2011
  • 负责人:
    ROBERT James MASON
  • 依托单位:
Air/liquid interface cultures for alveolar type II cell differentiation
  • 批准号:
    8279217
  • 项目类别:
  • 资助金额:
    $19.81万
  • 财政年份:
    2011
  • 负责人:
    ROBERT James MASON
  • 依托单位:
Alveolar type II cell innate immune response to influenza
  • 批准号:
    8074270
  • 项目类别:
  • 资助金额:
    $24.72万
  • 财政年份:
    2009
  • 负责人:
    ROBERT James MASON
  • 依托单位:
Alveolar type II cell innate immune response to influenza
  • 批准号:
    8063939
  • 项目类别:
  • 资助金额:
    $43.4万
  • 财政年份:
    2009
  • 负责人:
    ROBERT James MASON
  • 依托单位:
国内基金
海外基金
CAFs源性TNFα上调口腔鳞癌HLA-E表达促进NK免疫逃逸的机制研究
  • 批准号:
    32000552
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    王晓宁
  • 依托单位:
肿瘤相关成纤维细胞通过Hh-PI3K-AKT通路支持食管鳞状细胞癌细胞的增殖
  • 批准号:
    31960153
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    36.0万元
  • 批准年份:
    2019
  • 负责人:
    杨凌
  • 依托单位:
尾加压素II介导血管外膜氧化应激促进血管重构的作用研究
  • 批准号:
    81141003
  • 项目类别:
    专项基金项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2011
  • 负责人:
    丁文惠
  • 依托单位:
MicroRNA-21调控卵巢癌相关成纤维细胞转化介导的促肿瘤演进研究
  • 批准号:
    81101973
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2011
  • 负责人:
    姚勤
  • 依托单位: